CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

Stock Information for Telomir Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Telomir Pharmaceuticals Inc.

U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
CorMedix to Participate in Needham Virtual Healthcare Conference
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
CorMedix to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.